An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines

Neuroscience

Volumn 210, Issue , 2012, Pages 21-32

  Dafnis, I ^a   Tzinia, A K ^a   Tsilibary, E C ^a   Zannis, V I ^b   Chroni, A ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Apolipoprotein E; Apolipoprotein E4 fragments; Cytokines; Matrix metalloproteinase 9; Neuroinflammation

Indexed keywords

APOLIPOPROTEIN E4; BRAIN PROTEIN; CYTOKINE; GELATINASE B; INTERLEUKIN 1BETA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; ASTROCYTOMA CELL; BRAIN CELL; BRAIN LEVEL; CONTROLLED STUDY; ENZYME REGULATION; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION; IL 10 GENE; IL 1BETA GENE; INFLAMMATION; MOLECULAR WEIGHT; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; TNF ALPHA GENE;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; ASTROCYTES; BLOTTING, WESTERN; BRAIN; CELL LINE, TUMOR; CYTOKINES; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASE 9; NEURONS; PEPTIDE FRAGMENTS; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFECTION;

EID: 84861190052     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.03.013     Document Type: Article

References (73)

1. Abramoff M.D., Magelhaes P.J., Ram S.J. Image processing with ImageJ. Biophotonics Int 2004, 11:36-42.
2. Anderson S.S., Wu K., Nagase H., Stettler-Stevenson W.G., Kim Y., Tsilibary E.C. Effect of matrix glycation on expression of type IV collagen, MMP-2, MMP-9 and TIMP-1 by human mesangial cells. Cell Adhes Commun 1996, 4:89-101.
3. Asahina M., Yoshiyama Y., Hattori T. Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol 2001, 20:60-63.
4. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007, 8:663-672.
5. Bayer T.A., Wirths O. Review on the APP/PS1KI mouse model: intraneuronal Abeta accumulation triggers axonopathy, neuron loss and working memory impairment. Genes Brain Behav 2008, 7(Suppl 1):6-11.
6. Bayer T.A., Wirths O. Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology?. Biochem Soc Trans 2011, 39:857-861.
7. Benzing W.C., Wujek J.R., Ward E.K., Shaffer D., Ashe K.H., Younkin S.G., Brunden K.R. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging 1999, 20:581-589.
8. Brecht W.J., Harris F.M., Chang S., Tesseur I., Yu G.Q., Xu Q., Dee F.J., Wyss-Coray T., Buttini M., Mucke L., Mahley R.W., Huang Y. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 2004, 24:2527-2534.
9. Bruno M.A., Mufson E.J., Wuu J., Cuello A.C. Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol 2009, 68:1309-1318.
10. Bugno M., Witek B., Bereta J., Bereta M., Edwards D.R., Kordula T. Reprogramming of TIMP-1 and TIMP-3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines. FEBS Lett 1999, 448:9-14.
11. Candelario-Jalil E., Yang Y., Rosenberg G.A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009, 158:983-994.
12. Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med 2007, 11:1227-1238.
13. Chang S., ran Ma T., Miranda R.D., Balestra M.E., Mahley R.W., Huang Y. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A 2005, 102:18694-18699.
14. Chen J., Li Q., Wang J. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci U S A 2011, 108:14813-14818.
15. Chen S., Averett N.T., Manelli A., LaDu M.J., May W., Ard M.D. Isoform-specific effects of apolipoprotein E on secretion of inflammatory mediators in adult rat microglia. J Alzheimers Dis 2005, 7:25-35.
16. Cho H.S., Hyman B.T., Greenberg S.M., Rebeck G.W. Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol 2001, 60:342-349.
17. Chroni A., Pyrpassopoulos S., Thanassoulas A., Nounesis G., Zannis V.I., Stratikos E. Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties. Biochemistry 2008, 47:9071-9080.
18. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
19. Crocker S.J., Milner R., Pham-Mitchell N., Campbell I.L. Cell and agonist-specific regulation of genes for matrix metalloproteinases and their tissue inhibitors by primary glial cells. J Neurochem 2006, 98:812-823.
20. Dafnis I., Stratikos E., Tzinia A., Tsilibary E.C., Zannis V.I., Chroni A. An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42. J Neurochem 2010, 115:873-884.
21. Downen M., Amaral T.D., Hua L.L., Zhao M.L., Lee S.C. Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia 1999, 28:114-127.
22. Dzwonek J., Rylski M., Kaczmarek L. Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett 2004, 567:129-135.
23. Egensperger R., Kosel S., von Eitzen U., Graeber M.B. Microglial activation in Alzheimer disease: association with APOE genotype. Brain Pathol 1998, 8:439-447.
24. Frank-Cannon T.C., Alto L.T., McAlpine F.E., Tansey M.G. Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol Neurodegener 2009, 4:47.
25. Gardner J., Ghorpade A. Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res 2003, 74:801-806.
26. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
27. Gottschall P.E., Yu X. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem 1995, 64:1513-1520.
28. Guo L., LaDu M.J., Van Eldik L.J. A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity. J Mol Neurosci 2004, 23:205-212.
29. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007, 8:101-112.
30. Harris F.M., Brecht W.J., Xu Q., Tesseur I., Kekonius L., Wyss-Coray T., Fish J.D., Masliah E., Hopkins P.C., Scearce-Levie K., Weisgraber K.H., Mucke L., Mahley R.W., Huang Y. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A 2003, 100:10966-10971.
31. Heneka M.T., O'Banion M.K., Terwel D., Kummer M.P. Neuroinflammatory processes in Alzheimer's disease. J Neural Transm 2010, 117:919-947.
32. Hernandez-Guillamon M., Delgado P., Ortega L., Pares M., Rosell A., Garcia-Bonilla L., Fernandez-Cadenas I., Borrell-Pages M., Boada M., Montaner J. Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by beta-amyloid 25-35 fragment. J Neurosci Res 2009, 87:2115-2125.
33. Huang Y., Liu X.Q., Wyss-Coray T., Brecht W.J., Sanan D.A., Mahley R.W. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A 2001, 98:8838-8843.
34. Johnston H., Boutin H., Allan S.M. Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem Soc Trans 2011, 39:886-890.
35. Jones P.B., Adams K.W., Rozkalne A., Spires-Jones T.L., Hshieh T.T., Hashimoto T., von Armin C.A., Mielke M., Bacskai B.J., Hyman B.T. Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brain. PLoS ONE 2011, 6:e14586.
36. Kay A.D., Petzold A., Kerr M., Keir G., Thompson E.J., Nicoll J.A. Cerebrospinal fluid apolipoprotein E concentration decreases after traumatic brain injury. J Neurotrauma 2003, 20:243-250.
37. Kettlun A.M., Cartier L., Garcia L., Collados L., Vasquez F., Ramirez E., Valenzuela M.A. TIMPs and MMPs expression in CSF from patients with TSP/HAM. Life Sci 2003, 72:2863-2876.
38. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
39. Koronyo-Hamaoui M., Ko M.K., Koronyo Y., Azoulay D., Seksenyan A., Kunis G., Pham M., Bakhsheshian J., Rogeri P., Black K.L., Farkas D.L., Schwartz M. Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J Neurochem 2009, 111:1409-1424.
40. Kypreos K.E., Zannis V.I. Pathway of biogenesis of apolipoprotein E - containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem J 2007, 403:359-367.
41. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007, 8:499-509.
42. Li X., Kypreos K., Zanni E.E., Zannis V. Domains of apoE required for binding to apoE receptor 2 and to phospholipids: implications for the functions of apoE in the brain. Biochemistry 2003, 42:10406-10417.
43. Locati M., Deuschle U., Massardi M.L., Martinez F.O., Sironi M., Sozzani S., Bartfai T., Mantovani A. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J Immunol 2002, 168:3557-3562.
44. Lorenzl S., Albers D.S., LeWitt P.A., Chirichigno J.W., Hilgenberg S.L., Cudkowicz M.E., Beal M.F. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 2003, 207:71-76.
45. Lorenzl S., Albers D.S., Relkin N., Ngyuen T., Hilgenberg S.L., Chirichigno J., Cudkowicz M.E., Beal M.F. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int 2003, 43:191-196.
46. Lynch J.R., Tang W., Wang H., Vitek M.P., Bennett E.R., Sullivan P.M., Warner D.S., Laskowitz D.T. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003, 278:48529-48533.
47. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 2006, 103:5644-5651.
48. McGeer E.G., McGeer P.L. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 2010, 19:355-361.
49. Mizoguchi H., Takuma K., Fukuzaki E., Ibi D., Someya E., Akazawa K.H., Alkam T., Tsunekawa H., Mouri A., Noda Y., Nabeshima T., Yamada K. Matrix metalloprotease-9 inhibition improves amyloid beta-mediated cognitive impairment and neurotoxicity in mice. J Pharmacol Exp Ther 2009, 331:14-22.
50. Myers R.H., Schaefer E.J., Wilson P.W., D'Agostino R., Ordovas J.M., Espino A., Au R., White R.F., Knoefel J.E., Cobb J.L., McNulty K.A., Beiser A., Wolf P.A. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study. Neurology 1996, 46:673-677.
51. Nagaeva O., Jonsson L., Mincheva-Nilsson L. Dominant IL-10 and TGF-beta mRNA expression in gammadeltaT cells of human early pregnancy decidua suggests immunoregulatory potential. Am J Reprod Immunol 2002, 48:9-17.
52. Peress N., Perillo E., Zucker S. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J Neuropathol Exp Neurol 1995, 54:16-22.
53. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
54. Rasmussen R. Quantification on the LightCycler. Rapid cycle Real-time PCR, methods and applications 2001, 21-34. Spronger Press, Heidelberg. S. Meuer, C. Wittwer, K. Nakagawara (Eds.).
55. Remarque E.J., Bollen E.L., Weverling-Rijnsburger A.W., Laterveer J.C., Blauw G.J., Westendorp R.G. Patients with Alzheimer's disease display a pro-inflammatory phenotype. Exp Gerontol 2001, 36:171-176.
56. Shaftel S.S., Griffin W.S., O'Banion M.K. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 2008, 5:7.
57. Siest G., Bertrand P., Qin B., Herbeth B., Serot J.M., Masana L., Ribalta J., Passmore A.P., Evans A., Ferrari M., Franceschi M., Shepherd J., Cuchel M., Beisiegel U., Zuchowsky K., Rukavina A.S., Sertic J., Stojanov M., Kostic V., Mitrevski A., Petrova V., Sass C., Merched A., Salonen J.T., Tiret L., Visvikis S. Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group. Clin Chem Lab Med 2000, 38:721-730.
58. Stellwagen D., Malenka R.C. Synaptic scaling mediated by glial TNF-alpha. Nature 2006, 440:1054-1059.
59. Stomrud E., Bjorkqvist M., Janciauskiene S., Minthon L., Hansson O. Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimers Res Ther 2010, 2:20.
60. Strle K., Zhou J.H., Shen W.H., Broussard S.R., Johnson R.W., Freund G.G., Dantzer R., Kelley K.W. Interleukin-10 in the brain. Crit Rev Immunol 2001, 21:427-449.
61. Suryadevara R., Holter S., Borgmann K., Persidsky R., Labenz-Zink C., Persidsky Y., Gendelman H.E., Wu L., Ghorpade A. Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia 2003, 44:47-56.
62. Vedhachalam C., Narayanaswami V., Neto N., Forte T.M., Phillips M.C., Lund-Katz S., Bielicki J.K. The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry 2007, 46:2583-2593.
63. Vezeridis A.M., Chroni A., Zannis V.I. Domains of apoE4 required for the biogenesis of apoE-containing HDL. Ann Med 2011, 43:302-311.
64. Wang L., Han Y., Chen D., Xiao Z., Xi Z., Xiao F., Wang X. Cerebrospinal fluid apolipoprotein E concentration decreases after seizure. Seizure 2010, 19:79-83.
65. Wellnitz S., Friedlein A., Bonanni C., Anquez V., Goepfert F., Loetscher H., Adessi C., Czech C. A 13 kDa carboxy-terminal fragment of ApoE stabilizes Abeta hexamers. J Neurochem 2005, 94:1351-1360.
66. Wetterau J.R., Aggerbeck L.P., Rall S.C., Weisgraber K.H. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem 1988, 263:6240-6248.
67. Wilson C., Mau T., Weisgraber K.H., Wardell M.R., Mahley R.W., Agard D.A. Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein. Structure 1994, 2:713-718.
68. Wilson C., Wardell M.R., Weisgraber K.H., Mahley R.W., Agard D.A. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991, 252:1817-1822.
69. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 2006, 12:1005-1015.
70. Yan P., Hu X., Song H., Yin K., Bateman R.J., Cirrito J.R., Xiao Q., Hsu F.F., Turk J.W., Xu J., Hsu C.Y., Holtzman D.M., Lee J.M. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 2006, 281:24566-24574.
71. Zannis V.I., Breslow J.L., Utermann G., Mahley R.W., Weisgraber K.H., Havel R.J., Goldstein J.L., Brown M.S., Schonfeld G., Hazzard W.R., Blum C. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res 1982, 23:911-914.
72. Zannis V.I., Kypreos K.E., Chroni A., Kardassis D., Zanni E.E. Lipoproteins and atherogenesis. Molecular mechanisms of atherosclerosis 2004, 111-174. Taylor & Francis, Abington, UK. J. Loscalzo (Ed.).
73. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.